ST Tiansheng (002872.SZ): Isoniazid tablets passed generic drug consistency evaluation

Zhitongcaijing · 10/14 12:25

Zhitong Finance App News, ST Tiansheng (002872.SZ) issued an announcement. The company recently received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration. The company's “isoniazid tablets” passed the consistent evaluation of the quality and efficacy of generic drugs.

Isoniazid inhibits the synthesis of mycotic acid, a key component of bacterial cell walls. At therapeutic concentrations, isoniazid has a bactericidal effect on both intracellular and extracellular Mycobacterium tuberculosis during growth and reproduction. Isoniazid tablets are suitable for: (1) treatment of various types of tuberculosis sensitive to isoniazid in combination with other anti-tuberculosis drugs; (2) prevention of tuberculosis; (3) based on domestic clinical experience, this product can also be used in combination with other anti-tuberculosis drugs, and can also be used for other mycobacterial infections. Isoniazid tablets belong to the “National Essential Drug Catalogue (2018)” variety and the “National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2023)” category A.